Abstract
It is well recognised that haemodialysis and renal transplant patients are at increased risk of developing non-A, non-B hepatitis. Recently the genome of hepatitis C virus (HCV), the major causative agent for non-A, non-B hepatitis, has been isolated.
Anti-HCV seroprevalence was assessed in all haemodialysis patients (266) in Ireland who in March 1990 had been dialysed for at least 6 months. For comparative purposes, 272 patients who had functioning renal transplants for greater than 6 months were also studied. Potential risk factors such as age, number of blood transfusions and time on dialysis were evaluated.
The prevalence of HCV infection as evidenced by antibody detection was only 1.1% for transplant and 1.7% for haemodialysis patients. This compares to a reported incidence of between 10% and 50% found elsewhere. Two of the 5 anti-HCV positive haemodialysis patients and 2 of the 3 transplant patients had biochemical evidence of liver disease. From stored sera it was possible to ascertain when patients acquired HCV.
Whether the very low prevalence of anti-HCV in Irish patients is due to the low prevalence of the virus in the general population, the policy of non reimbursement of blood donors, genetic or other factors, remains to be determined.
Similar content being viewed by others
References
Nielson V., Clausen E., Ranek L. Liver impairment during chronic haemodialysis and after renal transplantation. Acta Med Scand. 1975;197:229–234.
Weir M.R., Kirkmann R.L., Strom T.B., Tilney N.L. et al. Liver disease in recipients in of long-functioning renal allografts. Kidney International. 1985;28:839–844.
Toussaint C, Dupont E., Vanherweghem J.L., Cappel R., et al. liver disease in patients undergoing haemodialysis and kidney transplantation. Nephrology Yearbook 1979.269–293.
Huang C.C., Lai M.K., Fong M.I. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation. 1990;49:540–544.
Feinstone S., Kapikan A., Purcell R., Alter H. et al. Tranfusion- associated hepatitis not due to viral hepatitis type A or B. The New England Journal of Medicine. 1975;292:767–770.
Galbraith R., Portmann B., Eddelstown A.L., Williams R. Chronic liver disease developing after an outbreak of HbsAgnegative hepatitis in haemodialysis unit. Lancet 1975;887–890.
Rakela J., Redker A.G. Chronic liver disease after acute non-A, non-B viral hepatitis. Gastroenterology. 1979;77:1200–1200.
Berman M., Alter H.J., Ishak G., Purcell R.H. The chronic sequelae of non-A, non-B hepatitis. Annals of Internal Medicine 1979;91:1–6.
Koretz R., Stone O., Gitnick G. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology 1980;79:893–898.
Knodell R., Conrad M., Ishak K. Development of chronic liver disease after acute non-A,non-B post transfusion hepatitis. Gastroenterology 1977;72:902–909.
Choo Q.L., Kuo G. Weiner A. J. Overby L.R. et al. Isolation of a cDN A clone derived from a blood borne non-A, non-B viral hepatitis genome. Science.1989;244:359–361.
Kuo G., Alter C., Gitnick G.L. Redeker A-G. et al. Anassay for circulating antibodies to a major etiologic virus of human non- A, non-B hepatitis. Science 1989;244:362–364.
Van Der Poel C.L., Reesink H.W., Leliei P.N., Leentvaar- Kuypers A. et al. Anti-hepatitis C antibodies and non-A, non-B post transfusion hepatitis in the Netherlands. Lancet 1989;297–298.
Esteban J.I., Esteban R., Viladomiu L., Lopez-Talavera J.C. et al. Hepatitis C virus antibodies among risk groups in Spain.
Zuckerman A.J. The elusive hepatitis C virus. British Medical Journal 1989; 299:871–872.
Will the real hepatitis C stand up. Lancet 1989;307–308.
Tremolada F., Casarin C, Tagger A., Ribero M.L. et at. Antibody to hepatitis C virus in post-transfusion hepatitis. Annals of Internal Medicine.1991;114:277–281.
Schlipkoter U., Roggendorf M., Ernst G., Rasshofer R. et al. Hepatitis C antibodies in haemodialysis patients. Lancet. 1990; 1409–1410.
Antibodies against hepatitis C virus (ant-HCV) in haemodialysis patients: Association with hepatitis B serological markers. Nephrology Dialysis and Transplantation. 1991;6:466–475.
Gilli P., Moretti M., Soffritti S., Menini C. Anti- HCV positive patients in dialysis units? Lancet 1990;336:243.
Mondelli M., Smedile V., Piazza V., Villa G. et al. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. Nephrology Dialysis and Transplantation 1991;6:480–483.
Hoofangle J., Gerety R., Tabor E., Feinstone S. et al. Transmission of non-A, non-B hepatitis. Annals of Internal Medicine. 1987;87:14–20.
Walsh T.J. Hepatitis C-Screening of blood donations. Irish Medical Journal.1991;84:41–42.
Rumi M.G., Colombo M., Gringeri A., Mannuccio P. et al. High prevalence of antibody to hepatitis C virus in multitransfussed haemophiliacs with normal transaminase levels. Annals of Internal Medicine. 1990; 112:379–380.
Garson J.A., Tuke P.W., Markis M., Briggs M. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis C virus containing factor Viii concentrates. Lancet 1990; 336:1022–25.
Farci P., Alter H.J., Wong D., Miller R.H. et al. A long-term study of hepatitis C virus replication in non-A, non-B Hepatitis. The New England Journal of Medicine. 1991;325:98–104.
Fagan E.A. Testing for hepatitis C virus. British Medical Journal 1991;303:535–6.
Van der Poel C.L. Cuypers H.T.M. Reesnink H.W. et al. Confirmation of hepatitis C virus infection by new four antigen-recombinant immunoblot assay. Lancet 1991;337:317–9.
Cantu P., Mangano S., Masini L. et al. Prevalence of antibodies against hepatitis C virus in adialysis unit. Nephron 1992;61:337–338.
Mondelli M.U., Cristina G., Piazza V. Cerino A. et al. High prevalence of antibodies to hepatitis C virus in haemodialysis units using a second generation assay. Nephron 1992;61: 350–351.1
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Conlon, P.J., Walshe, J.J., Smyth, E.G. et al. Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland. I.J.M.S. 162, 145–147 (1993). https://doi.org/10.1007/BF02942105
Issue Date:
DOI: https://doi.org/10.1007/BF02942105